SCHEMBL1800324

SCHEMBL1800324

C[C@H]1CCCN1CC1CCCN1C(=O)c1ccc(O)cc1F

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
PREP P48147 1/20 0.41
HSP90AA1 P07900 5/20 0.41
HSP90AB1 P08238 5/20 0.41
CPS1 P31327 3/20 0.40
KCNH2 Q12809 3/20 0.40
HRH3 Q9Y5N1 3/20 0.40
CYP3A4 P08684 2/20 0.40
PDE4B Q07343 2/20 0.40
PIK3CA P42336 2/20 0.37
MTOR P42345 2/20 0.37
MLLT1 Q03111 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1800327 1.00 POLB (0.42) POLBHPGDPREPHSP90AA1HSP90AB1
SCHEMBL12616256 1.00 POLB (0.42) POLBHPGDPREPHSP90AA1HSP90AB1
SCHEMBL2743789 0.88 HPGD (0.42) POLBHPGDPREPCPS1KCNH2
SCHEMBL6734430 0.88 HPGD (0.42) POLBHPGDPREPCPS1KCNH2
SCHEMBL2743790 0.88 HPGD (0.42) POLBHPGDPREPCPS1KCNH2
SCHEMBL1796952 0.84 HRH3 (0.51) KCNH2HRH3
SCHEMBL1796953 0.84 HRH3 (0.51) KCNH2HRH3
SCHEMBL12393111 0.83 PIK3CA (0.40) POLBHPGDPREPCPS1KCNH2
SCHEMBL12392878 0.83 PIK3CA (0.40) POLBHPGDPREPCPS1KCNH2
SCHEMBL12102162 0.82 MAOB (0.51) CPS1KCNH2HRH3CYP3A4PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP claimed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US claimed
US-7951826-B2 Obesity; cognition activators; narcolepsy ELI LILLY AND COMPANY (US) 2011-05-31 US disclosed
US-7846950-B2 Histamine H3 receptor inhibitors, preparation and therapeutic uses ELI LILLY AND COMPANY (US) 2010-12-07 US disclosed
EP-1861360-B1 PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-12-02 EP disclosed
EP-1805169-B1 HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2008-12-24 EP disclosed
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses JESUDASON CYNTHIA D 2008-01-17 US disclosed
EP-1805169-A1 HISTAMINE H3 RECEPTOR INHIBITORS, THEIR PREPARATION AND THERAPEUTIC USES Eli Lilly and Company (US) 2007-07-11 EP disclosed
WO-2006044228-A1 HISTAMINE H3 RECEPTOR INHIBITORS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207732-A1 Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists HRH3, HCRTR1, HRH4 POLB 2780/4885HPGD 713/4885PREP 268/4885
US-20080015235-A1 Histamine H3 Receptor Inhibitors, Preparation and Therapeutic Uses HRH3, HRH4, HCRTR1 POLB 4562/4885HPGD 1219/4885PREP 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.